Search results for " Ly"

showing 10 items of 2487 documents

Production of T suppressor factor specific for the hapten picryl chloride requires both T suppressor cells and an antigen-specific, genetically restr…

1987

Summary We investigated the requirement for activation of T suppressor cells specific for the hapten picryl chloride and the release of hapten-specific T suppressor factor. Using an in vivo experimental system, we report that activation of T suppressor cells and the consequent release of T suppressor factor required two signals: one was provided by primed T suppressor cells, i.e. spleen cells from mice injected with the tolerogen picrylsulphonic acid, and the other was provided by the specific antigen in the context of H-2 gene products. Mechanisms by which the interaction between these two signals led to activation of T suppressor cells and the production of T suppressor factor, as well as…

MaleMice Inbred StrainsPicryl ChlorideBiologyT-Lymphocytes Regulatorylaw.inventionPicryl chlorideEpitopesMicechemistry.chemical_compoundInterleukin 21AntigenlawSuppressor Factors ImmunologicAnimalsCytotoxic T cellDisulfidesCells CulturedGeneral Environmental ScienceH-2 AntigensLymphokineGeneral MedicineT lymphocyteCell biologychemistryImmunologyGeneral Earth and Planetary SciencesSuppressorFemaleHaptensOxidation-ReductionHaptenSpleenAnnales de l'Institut Pasteur / Immunologie
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct

The NK Cell Response to Mouse Cytomegalovirus Infection Affects the Level and Kinetics of the Early CD8+ T-Cell Response

2012

ABSTRACT Natural killer (NK) cells and CD8 + T cells play a prominent role in the clearance of mouse cytomegalovirus (MCMV) infection. The role of NK cells in modulating the CD8 + T-cell response to MCMV infection is still the subject of intensive research. For analyzing the impact of NK cells on mounting of a CD8 + T-cell response and the contribution of these cells to virus control during the first days postinfection (p.i.), we used C57BL/6 mice in which NK cells are specifically activated through the Ly49H receptor engaged by the MCMV-encoded ligand m157. Our results indicate that the requirement for CD8 + T cells in early MCMV control inversely correlates with the engagement of Ly49H. W…

MaleMuromegalovirusImmunologyNK cellsCD8-Positive T-LymphocytesBiologym157MicrobiologyRodent DiseasesMice03 medical and health sciencesInterleukin 210302 clinical medicineVirologyAnimalsCytotoxic T cellmouse cytomegalovirus; NK cells; T-cell response; Ly49H; m157IL-2 receptor030304 developmental biologyMice Inbred BALB C0303 health sciencesJanus kinase 3ZAP70BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Herpesviridae InfectionsNatural killer T cellMouse cytomegalovirus3. Good healthKiller Cells NaturalMice Inbred C57BLKineticsT-cell responseInsect ScienceImmunologyInterleukin 12CytokinesPathogenesis and ImmunityFemaleLy49HBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8030215 immunology
researchProduct

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study

2013

Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The rela…

MaleMyeloidMyeloproliferative disorders -- DiagnosisMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesMyelodysplastic Syndromes/embryology/mortalityRegistriesCàncerCancerAged 80 and overMielomeseducation.field_of_studyRelative survivalMyeloid leukemiaArticlesHematologyMiddle AgedEuropemedicine.anatomical_structureMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityAplastic anemia -- TreatmentFemaleAdultmedicine.medical_specialtyAdolescentPopulationMyelodysplastic syndromesmyeloid malignancies; survivalmyeloid malignanciesBone marrow -- TumorssurvivalNOEurope/epidemiologyYoung AdultInternal medicinemedicineHumanseducationSurvival analysisddc:613AgedMedul·la òssia -- TumorsEssential thrombocythemiabusiness.industryMyelodysplastic syndromesmedicine.diseaseThrombocytopeniaMyelodysplastic-Myeloproliferative DiseasesSurvival AnalysisMyelodysplastic SyndromesImmunologyMyélomesbusiness
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Are antiphospholipid antibodies an essential requirement for an effective immune response to infections?

2007

Antiphospholipid antibodies show a close association to a variety of infections. Recent data implicate that parvovirus B19 may be used as a model-system for studying the interaction of viral infection and the development of these autoantibodies. B19-related diseases commonly associated with the acute infection show flu-like symptoms, transient arthralgias, leukopenia and thrombocytopenia, and, in pregnant women, spontaneous abortion and hydrops fetalis. Hepatitis, myocarditis, meningitis, encephalitis, as well as pure red cell anemia may occur occasionally. In addition, parvovirus B19 infections have been frequently described as the cause or trigger of various forms of autoimmune diseases a…

MaleMyocarditisvirusesBiologymedicine.disease_causeInfectionsGeneral Biochemistry Genetics and Molecular BiologyParvoviridae InfectionsMiceHistory and Philosophy of SciencePregnancyhemic and lymphatic diseasesHydrops fetalismedicineParvovirus B19 HumanAnimalsHumansPregnancy Complications InfectiousAnti-neutrophil cytoplasmic antibodyHepatitisParvovirusGeneral NeuroscienceMolecular MimicryAutoantibodyvirus diseasesmedicine.diseasebiology.organism_classificationVirologyMolecular mimicryImmunologybiology.proteinAntibodies AntiphospholipidFemaleAntibodyAnnals of the New York Academy of Sciences
researchProduct

[Bilateral testicular lymphoma. Case report]

2008

A case of bilateral testicular lymphoma with involvement of skin and oropharynx was described. After a review of literature, the Authors underline the clinical features focusing the diagnostic approaches and the therapeutics options.

MaleNeoplasms Multiple PrimaryLymphomaTesticular NeoplasmsHumanstesticular lymphomaMiddle Aged
researchProduct

Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin

2005

OBJECTIVE: Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role in erythropoiesis. Recent studies have demonstrated that EPO and its receptor (EPO-R) are expressed in the central nervous system, where EPO exerts neuroprotective functions. Because the expression of the EPO and EPO-R network is poorly investigated in the central nervous system, the aim of the present study was to investigate whether the resident EPO and EPO-R network is activated in the injured nervous system. METHODS: A well-standardized model of compressive spinal cord injury in rats was used. EPO and EPO-R expression was determined by immunohistochemical analysis at 8 hours and at 2, 8, and 14 …

MaleNervous systemmedicine.medical_specialtyCentral nervous systemSpinal cord injuryNeuroprotectionErythropoietin receptorRats Sprague-Dawleyhemic and lymphatic diseasesInternal medicineReceptors ErythropoietinmedicineAnimalsSpinal cord injuryErythropoietinSpinal Cord InjuriesNeuronsbusiness.industryNervous tissuemedicine.diseaseAneurysmRecombinant ProteinsNeuroprotectionRatsErythropoietin receptorDisease Models Animalmedicine.anatomical_structureEndocrinologyGene Expression Regulationerythropoietin; erythropoietin receptor; neuroprotection; spinal cord injuryErythropoietinImmunologyNeurogliaSurgeryNeurology (clinical)businessSpinal Cord Compressionmedicine.drug
researchProduct

Behaviour of the neutrophil to lymphocyte ratio in young subjects with acute myocardial infarction

2016

In the last years the neutrophil to lymphocyte ratio (NLR) has been examined in cardiovascular disorders and in particular in coronary artery disease and acute myocardial infarction (AMI). Now we examined this parameter in subjects with juvenile myocardial infarction at the initial stage and after 3 and 12 months. We enrolled 123 young subjects (112 men and 11 women, mean age 39.4 ± 5.8 yrs) with AMI. The time interval between the AMI onset and the investigation was 13 ± 7 days. The mean value of NLR observed in young AMI subjects was significantly increased compared to normal controls (N = 1.817 ± 0.711; young AMI subjects = 2.376 ± 0.873, p <  0.0001). NLR does not discriminate STEMI (2.4…

MaleNeutrophilsPhysiologyLymphocyteMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseLeukocyte Count0302 clinical medicineRetrospective StudieRisk FactorsMedicineLymphocytes030212 general & internal medicineMyocardial infarctionStage (cooking)HematologyNeutrophilSmokingJuvenile myocardial infarction; leukocyte count; neutrophil/lymphocyte ratio; Adult; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Inflammation; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myocardial Infarction; Neutrophils; Prognosis; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Smoking; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)HematologyMiddle AgedPrognosismedicine.anatomical_structureAbsolute neutrophil countCardiologyLymphocyteFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosi03 medical and health sciencesPhysiology (medical)Internal medicineHumansLymphocyte Countcardiovascular diseasesNeutrophil to lymphocyte ratioRetrospective StudiesInflammationbusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseJuvenile myocardial infarctionneutrophil/lymphocyte ratioST Elevation Myocardial InfarctionbusinessBiomarkersClinical Hemorheology and Microcirculation
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct